Shares of Vir Biotechnology, Inc. (NASDAQ: VIR) advanced 10.80% on November 6, 2026, closing at $12.21, up $1.19 from the previous close of $11.02. The stock continued higher in premarket trading on November 9, reaching $14.40, a further gain of 17.94% from Friday’s closing price. The move brought the biotechnology company’s market capitalization to approximately $2.09 billion based on the reported intraday figure.
Market Performance
Vir Biotechnology opened the November 6 session at $11.30 and traded between $11.30 and $12.44. Its closing price of $12.21 placed the stock near the upper end of that range. Trading volume reached approximately 1.90 million shares, slightly below its reported average volume of 1.95 million.
The stock’s five-day performance was approximately 8.05%, according to the displayed chart. Its 52-week trading range stood between $5.22 and $12.44, with the November 6 session high matching the reported annual high.
In premarket trading on November 9, shares were quoted at $14.40, up $2.19, or 17.94%, from the previous close. This extended the recent advance, although the premarket quotation does not represent a confirmed regular-session closing price.
Financial and Valuation Snapshot
Vir Biotechnology reported a market capitalization of approximately $2.09 billion. Its trailing twelve-month earnings per share stood at negative $1.18, while the price-to-earnings ratio was unavailable in the displayed market data.
The stock had a five-year monthly beta of 1.74, indicating relatively high historical price sensitivity compared with the broader market. Its one-year analyst target estimate was $21.50, above the November 6 closing price of $12.21.
Company Overview
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for serious infectious diseases. Founded in 2016 and headquartered in San Francisco, California, the company reported 367 full-time employees.
Its clinical pipeline includes investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. Its preclinical programs include candidates directed at influenza A and B, coronavirus, and PRO-XTEN, a dual-masked T-cell engager technology designed to target a variety of solid tumors.
Vir also maintains a number of research, licensing, and collaboration agreements with pharmaceutical and research organizations, including Astellas, Norgine, the Gates Foundation, Brii Biosciences, Alnylam Pharmaceuticals, the Institute for Research in Biomedicine, The Rockefeller University, Xencor, and GlaxoSmithKline Biologicals.
Upcoming Events and Market Outlook
The supplied company profile lists an earnings event for November 5, 2026, corresponding to November 4 in U.S. Eastern Time. The event date has passed relative to the November 9 premarket quotation.
The recent share-price advance places attention on Vir’s clinical development programs and its progress across infectious disease and oncology research. However, the available market information does not identify the specific catalyst behind the November 6 gains or the subsequent premarket increase.
Closing Insights
Vir Biotechnology entered November 9 with substantial upward momentum after gaining 10.80% in the previous regular session and advancing a further 17.94% in premarket trading. Its share price moved above the previously reported 52-week high, while the company’s market capitalization stood at approximately $2.09 billion. The sustainability of the move will depend on subsequent trading and developments in the company’s clinical pipeline, rather than the premarket quotation alone.
